Oncotarget

Research Papers:

Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer

Fei Song, Geng Wang, Zhifang Ma, Yuebing Ma and Yingying Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:95392-95400. https://doi.org/10.18632/oncotarget.20726

Metrics: PDF 480 views  |   HTML 751 views  |   ?  


Abstract

Fei Song1, Geng Wang2, Zhifang Ma3, Yuebing Ma3 and Yingying Wang3

1Department of General Surgery, Shandong Provincial Third Hospital, Jinan, Shandong, China

2Department of Emergency, Laiwu City People’s Hospital, Laiwu, Shandong, China

3Department of Gynecologic Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, China

Correspondence to:

Yingying Wang, email: wangyingyingsdszz@163.com

Keywords: BAG3, EMT, cervical cancer

Received: July 19, 2017     Accepted: August 04, 2017     Published: September 08, 2017

ABSTRACT

Bcl2-associated athanogene 3 (BAG3) has been reported to be involved in aggressive progression of many tumors. In the present study, we examined the expression of BAG3 in human cervical cancer (CC) tissues and investigated the role of BAG3 in SiHa and HeLa cell growth, migration, and invasion. Here, we found that most of CC tissues highly expressed the protein and mRNA of BAG3, while their expression was obviously lower in paired normal tissues (all p<0.001). BAG3 expression was associated with FIGO stage and metastasis (all p<0.05). In-vitro analysis demonstrated that BAG3 siRNAs inhibited SiHa and HeLa cell growth, invasion and migration. Mechanically, BAG3 siRNAs inhibited the expression of EMT-regulating markers, involving MMP2, Slug and N-cadherin, and increased the expression of E-cadherin. In a xenograft nude model, BAG3 siRNAs inhibited tumor growth and the expression of EMT biomarkers. In conclusion, BAG3 is involved in the EMT process, including cell growth, invasion and migration in the development of CC. Thus, BAG3 target might be recommended as a novel therapeutic approach.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20726